2024 Revenues ($USD) : $3.24B
Moderna reported $3.2B in revenue for 2024, a 52.75% decline from 2023, reflecting the anticipated drop in COVID-19 vaccine demand. The company has adjusted its 2025 revenue forecast to $1.5-2.5B, with most revenue expected in H2 2025. Despite these challenges, Moderna continues to diversify its portfolio beyond COVID-19, with recent approvals including the RSV vaccine in Australia and significant funding for its pandemic influenza program. Three new manufacturing plants coming online in 2025 aim to improve production efficiencies.